EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC-ND 4.0

Allogenic stem cells for Crohn's anal fistulas: Treating early improves the deep remission rate

Nadia Fathallah iD, Laurent Siproudhis, Mélissa Akaffou, Mohamed Amine Haouari, Amandine Landemaine, Elise Pommaret, Lucas Spindler, Charlène Brochard iD, Guillaume Bouguen iD, Vincent de Parades

Colorectal Disease · 2023

DOI: 10.1111/codi.16782 ↗

At a glance

Journal article in Colorectal Disease, 2023. Written by Nadia Fathallah and 9 co-authors. Institution: Department of Medicosurgical Proctology, Groupe Hospitalier Paris Saint Joseph, Paris, France. Major MEDLINE topics: Crohn Disease, Rectal Fistula. Cited 7 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Aim

The aim of this study was to evaluate the real‐life clinical and radiological efficacy of darvadstrocel injection into complex perianal fistulas in Crohn's disease. Secondary endpoints were to assess symptomatic efficacy, adverse effects and factors associated with complete combined clinical‐radiological response (deep remission).

Methods

After marketing the product in France, all first patients treated consecutively were included. A complete clinical response was defined by a complete closure of all external openings with no discharge on pressure. A complete radiological response (MRI), evaluated at least after six months of follow‐up, was defined by a completely fibrotic sequela without abscess. A deep remission was defined as the association of a complete clinical response with a complete radiological response.

Results

A total of 43 patients were included (M/F: 22/21, median age 37 [26–45] years). The fistulas were already drained with seton(s) and were on biologic treatment. After a median follow‐up of 383 (359–505) days, 28 (65%) patients showed a clinical response (22 complete and 6 partial) and 16 (37%) achieved a deep remission. The Perineal Disease Activity Index decreased significantly after treatment: 39 (91%) patients reported symptomatic improvement in terms of discharge, pain, and induration, and 28 (65%) no longer had any perineal symptoms. No severe adverse events were reported. A short history of Crohn's disease

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseRectal FistulaHumansAdultTreatment OutcomeCombined Modality TherapyStem CellsImmunosuppressive Agents

Author keywords

Crohn's diseaseanal fistuladarvadstroceldeep remissionstem cell therapy

Substances

Immunosuppressive Agents

Authors and institutions

  • Department of Medicosurgical Proctology, Groupe Hospitalier Paris Saint Joseph, Paris, France.
  • Gastroenterology, CHU-Ponchaillou, Rennes, France.
  • University Rennes 1, Rennes, France.
  • Department of Radiology, Groupe Hospitalier Paris Saint Joseph, Paris, France.
  • Physiology Unit, CHU-Ponchaillou, Rennes, France.

ORCID profiles: Nadia Fathallah, Charlène Brochard, Guillaume Bouguen

Cite

APA

Fathallah, N., Siproudhis, L., Akaffou, M., Haouari, M. A., Landemaine, A., Pommaret, E., Spindler, L., Brochard, C., Bouguen, G., & de Parades, V. (2023). Allogenic stem cells for Crohn's anal fistulas: Treating early improves the deep remission rate. Colorectal Disease. https://doi.org/10.1111/codi.16782

Vancouver

Fathallah N, Siproudhis L, Akaffou M, Haouari MA, Landemaine A, Pommaret E, et al. Allogenic stem cells for Crohn's anal fistulas: Treating early improves the deep remission rate. Colorectal Disease. 2023. doi:10.1111/codi.16782

BibTeX
@article{Fathallah2023,
  author = {Fathallah, Nadia and Siproudhis, Laurent and Akaffou, Mélissa and Haouari, Mohamed Amine and Landemaine, Amandine and Pommaret, Elise and Spindler, Lucas and Brochard, Charlène and Bouguen, Guillaume and de Parades, Vincent},
  title = {Allogenic stem cells for Crohn's anal fistulas: Treating early improves the deep remission rate},
  journal = {Colorectal Disease},
  year = {2023},
  doi = {10.1111/codi.16782}
}
Start for free →